Drug evaluation: adecatumumab, an engineered human anti-EpCAM antibody.

Abstract	Micromet Inc, in collaboration with Merck Serono SA, is developing adecatumumab for the potential treatment of adenocarcinomas, including breast and prostate cancer. Adecatunmumab is a fully human antibody targeting epithelial cell adhesion molecule (EpCAM). Adecatumumab is currently undergoing phase II clinical trials in breast and prostate cancer.
Authors	Irena Kirman, Richard L Whelan
Journal	Current opinion in molecular therapeutics (Curr Opin Mol Ther) Vol. 9 Issue 2 Pg. 190-6 (Apr 2007) ISSN: 1464-8431 [Print] England
PMID	17458174 (Publication Type: Journal Article)
Chemical References	Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antigens, Neoplasm Cell Adhesion Molecules EPCAM protein, human Epithelial Cell Adhesion Molecule adecatumumab
Topics	Antibodies, Monoclonal (adverse effects, pharmacokinetics, pharmacology) Antibodies, Monoclonal, Humanized Antigens, Neoplasm (immunology) Cell Adhesion Molecules (immunology) Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic Contraindications Drug Evaluation, Preclinical Epithelial Cell Adhesion Molecule Humans Patents as Topic Protein Engineering (methods) Structure-Activity Relationship

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!